Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
229.43B
Market cap229.43B
Price-Earnings ratio
14.09
Price-Earnings ratio14.09
Dividend yield
2.51%
Dividend yield2.51%
Average volume
31.49M
Average volume31.49M
High today
$49.40
High today$49.40
Low today
$48.08
Low today$48.08
Open price
$48.74
Open price$48.74
Volume
12.09M
Volume12.09M
52 Week high
$93.80
52 Week high$93.80
52 Week low
$43.08
52 Week low$43.08

NVO News

TipRanks 8m
Novo Nordisk CFO Sells DKK 8.4 Million in Company Shares

An update from Novo Nordisk ( (NVO) ) is now available. On 10 February 2026, Novo Nordisk’s Executive Vice President and Chief Financial Officer Karsten Munk K...

Seeking Alpha 30m
Many users of Novo Nordisk Wegovy pill new to GLP-1s - study

About 36% of individuals who are on Novo Nordisk's (NVO) Wegovy (semaglutide) pill, which hit the market in January, are new to GLP-1s, a new study found. Heal...

Many users of Novo Nordisk Wegovy pill new to GLP-1s - study
CNBC 2h
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Key Points Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what’s been described as a “show me” year. The Danish drugmaker kicked off 20...

Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Analyst ratings

53%

of 34 ratings
Buy
52.9%
Hold
35.3%
Sell
11.8%

More NVO News

TipRanks 5h
Novo Nordisk Maps Doctor Awareness on Inflammation, Signaling Future Cardio-Renal Strategy

Novo Nordisk (NVO) announced an update on their ongoing clinical study. This Novo Nordisk A/S survey, titled “Focus on Levels of Awareness and Perceptions Rega...

CNBC 5h
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs

Key Points Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments....

Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Nasdaq 6h
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.

Key Points Eli Lilly has a lofty 46 price-to-earnings ratio. Two other drugmakers have P/Es that are less than half of Eli Lilly's P/E. Eli Lilly's 0.6% yiel...

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
The Motley Fool 6h
Biotech Beat Nvidia in 2025. Can It Do It Again?

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperfor...

Biotech Beat Nvidia in 2025. Can It Do It Again?
24/7 Wall St. 9h
GLP-1 Lawsuits Are the Black Swan Risk Investors Aren't Watching

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren’t Watching Quick Read Over 3,300 lawsuits from 4,400+ plaintiffs target Novo Nordisk and Eli Lilly over G...

GLP-1 Lawsuits Are the Black Swan Risk Investors Aren't Watching
Simply Wall St 12h
Assessing Novo Nordisk Valuation After Recent Share Price Weakness

Advertisement Context for Novo Nordisk (NYSE:NVO) After Recent Share Moves Novo Nordisk (NYSE:NVO) has seen its share price under pressure recently, with a 16...

Assessing Novo Nordisk Valuation After Recent Share Price Weakness
Nasdaq 15h
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore

Key Points Viking Therapeutics is advancing weight loss candidates through phase 2 and phase 3 trials. Results so far have been very promising. 10 stocks we...

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.